Publications

Journal Article
Review
Epublish 4 citations
Electronic publication date
January 12, 2024

View on Pubmed.gov 38203341 | View on doi.org 10.3390/ijms250...

Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer's Disease.

Search for publications in this journal Int J Mol Sci

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disease worldwide and has a high incidence in the elderly. Unfortunately, there is no effective therapy for AD owing to its complicated pathogenesis. However, the development of lipid-lowering anti-inflammatory drugs has heralded a new era in the treatment of Alzheimer's disease. Several studies in recent years have shown that lipid metabolic dysregulation and neuroinflammation are associated with the pathogenesis of AD. 3-Hydroxyl 3-methylglutaryl CoA reductase (HMGCR) is a rate-limiting enzyme in cholesterol synthesis that plays a key role in cholesterol metabolism. HMGCR inhibitors, known as statins, have changed from being solely lipid-lowering agents to neuroprotective compounds because of their effects on lipid levels and inflammation. In this review, we first summarize the main regulatory mechanism of HMGCR affecting cholesterol biosynthesis. We also discuss the pathogenesis of AD induced by HMGCR, including disordered lipid metabolism, oxidative stress, inflammation, microglial proliferation, and amyloid-β (Aβ) deposition. Subsequently, we explain the possibility of HMGCR as a potential target for AD treatment. Statins-based AD treatment is an ascent field and currently quite controversial; therefore, we also elaborate on the current application prospects and limitations of statins in AD treatment.

References

Cell. 1985 May;41(1):249-58

J Parkinsons Dis. 2021;11(4):1651-1662

Biomed Res Int. 2022 Jun 6;2022:4558867

Neurosci Lett. 2007 Apr 6;416(1):66-70

Cited by 4 citations (total)

Journal Article Preprint

TNF-α disrupts the malate-aspartate shuttle, driving metabolic rewiring in iPSC-derived enteric neural lineages from Parkinson's Disease patients.

Electronic publication date April 8, 2025

Search for publications in this journal bioRxiv

Bruno Ghirotto [...] Beate Winner et al.

Gastrointestinal (GI) dysfunction emerges years before motor symptoms in Parkinson's disease (PD), implicating the enteric nervous system (ENS) in early...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances